

Super-TDU (1-31) (TFA)

Cat. No.:	HY-P1728A	
Molecular Formula:	$C_{141}H_{218}N_{40}O_{48}C_2HF_3O_2$	
Molecular Weight:	3355.5	
Sequence Shortening:	SVDDHFAKSLGDTWLQIGGSGNPKTANVPQT	SVDDHFAKSLGDTWLQIGGSGNPKTANVPQT (TFA salt)
Target:	YAP	
Pathway:	Stem Cell/Wnt	
Storage:	Sealed storage, away from moisture and light	
	Powder	-80°C 2 years -20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 50 mg/mL (14.90 mM; Need ultrasonic)					
		Solvent Concentration	Mass			
	Preparing Stock Solutions			1 mg	5 mg	10 mg
		1 mM		0.2980 mL	1.4901 mL	2.9802 mL
		5 mM		0.0596 mL	0.2980 mL	0.5960 mL
	10 mM		0.0298 mL	0.1490 mL	0.2980 mL	
Please refer to the solubility information to select the appropriate solvent.						

BIOLOGICAL ACTIVITY

Description	Super-TDU (1-31) TFA is a peptide fragment of Super-TDU. Super-TDU (1-31) TFA is an inhibitor of YAP-TEAD complex. Super-TDU TFA shows potent anti-tumor activity and suppresses tumor growth in gastric cancer mouse model ^{[1][2]} .									
In Vitro	<p>Super-TDU (1-31) TFA (50 nM; 24-72 hours) can largely compromise the increased cell viability induced by ACTN1 in Huh-7 or LM3 cells proliferation^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Liver cancer cell lines of human, including Huh-7, LM3 cells</td> </tr> <tr> <td>Concentration:</td> <td>50 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24, 48 and 72 h</td> </tr> <tr> <td>Result:</td> <td>Could largely compromise the increased cell viability induced by ACTN1.</td> </tr> </table>		Cell Line:	Liver cancer cell lines of human, including Huh-7, LM3 cells	Concentration:	50 nM	Incubation Time:	24, 48 and 72 h	Result:	Could largely compromise the increased cell viability induced by ACTN1.
Cell Line:	Liver cancer cell lines of human, including Huh-7, LM3 cells									
Concentration:	50 nM									
Incubation Time:	24, 48 and 72 h									
Result:	Could largely compromise the increased cell viability induced by ACTN1.									

CUSTOMER VALIDATION

- J Biomater Tiss Eng. 2020, 10(5):647-653.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Qian Chen, et al. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2021 Jan 7;40(1):23.
- [2]. Jiao S, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014 Feb 10;25(2):166-80.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA